Wedbush analyst Daniel Ives maintains Cerence (NASDAQ:CRNC) with a Neutral and raises the price target from $25 to $32.
Analyst Ratings For Accolade
Within the last quarter, Accolade (NASDAQ:ACCD) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago